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Abstract
Background: The aim of this study is to investigate whether body mass index (BMI) is a prognostic factor in gastric
cancer patients with peritoneal dissemination.
Methods: This is a retrospective study consisting of 518 patients with a histological diagnosis of gastric cancer with
peritoneal dissemination seen at the Sixth Affiliated Hospital of Sun Yat-Sen University and Sun Yat-sen University
Cancer Center between January 2010 and April 2014. Patients were followed until December 2015. Chi-square test
and Kaplan-Meier survival analysis were used to compare the clinicopathological variables and prognosis.
Results: Univariate analyses showed that significant prognostic factors included palliative gastrectomy (p < 0.001),
tumor size (p < 0.001), tumor location (p = 0.011), peritoneal seeding grade (p < 0.001), ascites (p = 0.001), serum CEA
level (p = 0.002), serum CA19-9 level (p = 0.033), palliative chemotherapy (p < 0.001), and BMI group (p < 0.001). For
patients with palliative chemotherapy, univariate analysis revealed that palliative gastrectomy (p < 0.001), tumor size
(p = 0.002), tumor location (p = 0.024), peritoneal seeding grade (p = 0.008), serum CEA level (p = 0.041), and BMI
group (p < 0.001). Multivariate analysis revealed that BMI was an independent prognostic factor in gastric cancer
patients with peritoneal dissemination, especially in patients who received palliative chemotherapy.
Conclusions: BMI is a prognostic factor for patients who have gastric cancer with peritoneal dissemination,
especially in those who received palliative chemotherapy.
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Background
In China, gastric cancer is the third most common can-
cer and the second leading cause of cancer-related death
[1]. And most patients with gastric cancer are diagnosed
with an advanced stage of the disease in China, some
even with metastatic disease [2, 3]. Peritoneal dissemin-
ation is the most common manifestation for late-stage
gastric cancer [4]. The prognosis of patients who have
gastric cancer with peritoneal dissemination is very poor,
even with the development of targeted therapy and
chemotherapy [5, 6]. Palliative gastrectomy is still con-
troversial for this group of patients. In clinic, we believed
that the nutritional status is an important factor that im-
pacts the treatment and prognosis of patients who have
gastric cancer with peritoneal dissemination.
Body mass index (BMI) is commonly used to assess
nutritional status [7]. According to the World Health
Organization’s (WHO) guidelines, BMI is divided into
three groups with 18.5 and 25 as the cutoff values for a
normal BMI level. However, in Asia, a BMI range of 18.5
to 23 is always used to classify people into the under-
weight group, normal range group, and overweight
group [8]. BMI has always been used as an indicator of
the status of patients. It had been reported that the BMI
would infect the surgical outcomes in colorectal cancer,
pancrea cancer, liver cancer, and so on. [9–13]. However,
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the controversy of the BMI on perioperative morbidity
still remained [14–17]. In a report by Pawlik et al. about
the BMI and gastric cancer, the overall survival of pa-
tients with underweight patients with a BMI <18.5 kg/
m2 after gastrectomy for cancer was worse than those
with BMI higher than 18.5 [18]. Hu et al. reported that a
low BMI was associated with more severe postoperative
complications and a poor prognosis, compared to pa-
tients with a normal BMI [19]. However, there are no re-
ports in the current literature that have examined the
relationship between BMI and the prognosis of patients
who have gastric cancer with peritoneal dissemination.
The aim of our study was to examine the relation-
ship between BMI and the prognosis of gastric can-
cer patients who have peritoneal dissemination.
Methods
Ethics approval and consent
All patients provided written informed consent for
their information to be stored in a hospital database.
A separate consent was obtained for the use of this
information for research purposes. Study approval
was obtained from independent ethics committees at
the Sixth Affiliated Hospital of Sun Yat-Sen Univer-
sity. This study was undertaken in accordance with
the ethical standards of the World Medical Associ-
ation Declaration of Helsinki.
Patients
Between January 2000 and April 2014, a total of
518 patients were histologically proven and diag-
nosed with gastric adenocarcinoma with peritoneal
metastasis in surgery in The Sixth Affiliated Hos-
pital of Sun Yat-sen University and Sun Yat-sen
University Cancer Center. Patients were divided into
three groups based on their BMI using 18.5 and 23
as the cutoff values. The clinicopathologic character-
istics and clinical outcomes of all 518 patients were
reviewed.
Table 1 Clinical pathological data for gastric cancer patients with different BMI groups
Clinical pathological data Fewer than 18.5
(n = 167 cases)
Between 18.5–23
(n = 232 cases)
Greater than 23
(n = 119 cases)
p value
Cases % Cases % Cases %
Age (years) Mean 52.6 52.9 53.3 –
Range 20–85 19–85 29–84
Sex Male 95 56.9 122 52.6 72 60.5
Female 72 43.1 110 47.4 47 39.5 0.347
Tumor location Gastric cardia 40 24.0 47 20.3 31 26.1
Middle 26 15.6 47 20.3 32 26.9
Antrum 63 37.7 92 39.7 36 30.3
Total stomach 38 22.8 46 19.8 20 16.8 0.181
Surgery Gastrectomy 90 53.9 165 71.1 75 63.0
No gastrectomy 77 46.1 67 28.9 44 37.0 0.002
Tumor size <5 cm 50 29.9 91 39.2 47 39.5
≥5 and <10 cm 83 49.7 104 44.8 56 47.1
≥10 cm 34 20.4 37 15.9 16 13.4 0.249
Serum CEA level <5 ng/ml 104 67.5 165 73.7 80 70.8
≥5 ng/ml 50 32.5 59 26.3 33 29.2 0.433
CA19-9 level <35 U/ml 91 59.9 151 69.3 72 63.7
≥35U/ml 61 40.1 67 30.7 41 36.3 0.166
Seeding gradea P1 28 16.8 66 28.4 42 35.3
P2 44 26.3 72 31.0 33 27.7
P3 95 56.9 94 40.5 44 37.0 0.001
Multi-site metastasis Without 97 58.1 181 78.0 81 68.1
With 70 41.9 51 22.0 38 31.9 < 0.001
Chemotherapy Without 77 46.1 68 29.3 36 30.3
With 90 53.9 164 70.7 83 69.7 0.001
aPeritoneal dissemination grade was divided into P1, P2, and P3 groups under the standard of first English version of Japanese classification of gastric carcinoma
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Patient inclusion criteria
The inclusion criteria were as follows: (1) WHO perform-
ance status of 0 to 1; (2) the patient underwent surgery
and had histologically proven gastric adenocarcinoma of
the stomach with peritoneal dissemination; (3) no
synchronous or metachronous cancers; (4) no history of
previous radiotherapy or other treatments, including im-
munotherapy or traditional Chinese medicine; and (5) no
prior gastric surgery.
Classification of peritoneal seeding
According to the first English edition of the Japanese
classification of gastric carcinoma, the degree of peri-
toneal metastasis was classified as follows: P0, no
peritoneal dissemination or seeding; P1, disseminating
metastasis to the region directly adjacent to the peri-
toneum of the stomach (above the transverse colon
including the greater omentum); P2, several scattered
metastases to the distant peritoneum and ovarian me-
tastasis alone; and P3, numerous metastases to the
distant peritoneum [20].
Follow-up
Following treatment, patients were monitored every
month for the first year, every 3 months for the sec-
ond year, and every 6 months thereafter. Telephone
calls and letters were used to follow-up patients who
were unable to attend regular follow-up assessments.
Complete data were collected for all 523 patients
through December 2015.
Fig. 1 The Kaplan-Meier analysis of the prognosis of this group of gastric cancer patients with peritoneal dissemination. Palliative gastrectomy (a),
tumor size (b), tumor location (c), peritoneal seeding grade (d), ascites (e), serum CEA level (f), serum CA19-9 level (g), palliative chemotherapy
(h), and BMI group (i) were significant prognostic factors in this cohort
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Statistical methods
A chi-square test was used to compare the categorical var-
iables between the palliative operative group and the other
groups. Student’s t test was used to compare continuous
variables. Univariate survival analyses were performed
using Kaplan-Meier methods. Survival curves were com-
pared using the log-rank test. Analyses were performed
using SPSS software v.20.0 (SPSS, Inc., Chicago, IL) for
Windows. Statistical significance was defined as p < 0.05.
Results
Patient demographics
Among the 518 patients with gastric cancer and periton-
eal dissemination, 330 underwent non-curative gastrec-
tomy, while 188 patients did not. Their median age was
59 years (range, 18–83). Of these patients, 289 were
male and 229 were female. The 1-year overall survival of
the entire cohort was 26.0%, with a median survival of
13.2 months. Patients were separated into three groups
based on their BMI with the cutoff values of 18.5 and
23. There were 167 patients with a BMI <18.5, 232 with
a BMI 18.5–23, and 119 patients with a BMI >23. The
patient clinicopathological characteristics are presented
in Table 1.
Univariate analyses of the prognosis of this group of
gastric cancer patients with peritoneal dissemination
Based on Kaplan-Meier analysis, palliative gastrec-
tomy (p < 0.001), tumor size (p < 0.001), tumor loca-
tion (p = 0.011), peritoneal seeding grade (p < 0.001),
ascites (p = 0.001), serum CEA level (p = 0.002),
serum CA19-9 level (p = 0.033), palliative chemotherapy
(p < 0.001), and BMI group (p < 0.001) were significant
Table 2 Univariate analysis of the overall survival in these group
gastric cancer patients with peritoneal dissemination











With 330 19 7.33
Without 188 31 16.13
Tumor size <0.001




>10 cm 87 18 9.30
Tumor location 0.011
Upper 118 23 12.00
Middle 105 30 15.60
Lower 191 39 13.33




P1 136 34 18.67
P2 149 31 15.48
P3 233 19 8.97
Ascite 0.001
With 207 20 9.87




Normal 349 29 14.03




Normal 314 29 13.53




Yes 337 35 17.40




<18.5 167 15 8.17
18.5–23 232 35 18.67
>23 119 25 11.87
Table 3 Multivariate analyses of the overall survival in gastric
cancer patients (Cox regression model)
Variable HR 95% CI p value
OS in gastric cancer patients
Palliative gastrectomy
(Gastrectomy vs. without gastrectomy)a
0.689 0.540–0.879 0.003
Tumor size
(<5, ≥5, and <10 vs. ≥10 cm)
1.176 0.999–1.383 0.051
Tumor location






(P1 and P2 vs. P3)









0.399 0.314–0.506 < 0.001
BMI group
(<18.5 and 18.5–23 vs. >23)
0.812 0.686–0.962 0.016
Abbreviations: OS overall survival, HR hazard ratio, CI confidence interval
aThe factor listed at the last was used as the control level in this Cox
regression model
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Fig. 2 The Kaplan-Meier analysis of the prognosis of this group of gastric cancer patients with peritoneal dissemination without palliative chemotherapy.
Palliative gastrectomy (a), tumor size (b), tumor location (c), peritoneal seeding grade (d), ascites (e), serum CEA level (f), serum CA19-9 level (g), and BMI
group (h) were prognostic risk factors
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prognostic factors in this cohort, and the results were
shown in Fig. 1. As shown in Table 2, the median survival
of patients based on BMI were 8.17 months in patients
with a BMI less than 18.5, 18.67 months for those with a
BMI between 18.5 and 23, and 11.87 months in patients
with a BMI greater than 23.
BMI value was an independent prognostic factor of
gastric cancer patients with peritoneal dissemination by
multivariate analyses
Cox regression model was used to identify the independ-
ent prognostic risk factors in patients with gastric cancer
and peritoneal seeding. The results revealed that pallia-
tive gastrectomy, peritoneal seeding grade, serum CEA
level, palliative chemotherapy, and BMI value were inde-
pendent prognostic risk factors. All of these results are
presented in Table 3.
Univariate analyses and multivariate analysis of the
prognosis of gastric cancer patients with peritoneal
dissemination without palliative chemotherapy
Patients were stratified based on having received pa-
lliative chemotherapy or not. Kaplan-Meier analysis
showed that palliative gastrectomy (p < 0.001), tumor
size (p = 0.049), tumor location (p = 0.002), peritoneal
seeding grade (p < 0.001), ascites (p = 0.017), serum CEA
level (p = 0.024), serum CA19-9 level (p = 0.014), and
BMI group (p = 0.008) were prognostic risk factors. All
of these results are presented in Fig. 2.
Only the tumor location and the peritoneal seeding
grade remained independent prognostic factors upon
Cox regression analysis, as shown in Table 4.
Univariate analyses and multivariate analysis of the
prognoses of gastric cancer patients with peritoneal
dissemination with palliative chemotherapy
As shown in Fig. 3, 337 patients received palliative
chemotherapy in this cohort. Results from Kaplan-
Meier analysis showed that the palliative gastrectomy
(p < 0.001), tumor size (p = 0.002), tumor location (p =
0.024), peritoneal seeding grade (p = 0.008), serum
CEA level (p = 0.041), and BMI group (p < 0.001) were
risk factors.
Multivariate analysis showed that palliative gastrectomy,
serum CEA level, and BMI group were independent prog-
nostic factors, as showed in Table 5.
Discussion
With the increasing prevalence of obesity that occurred
in China and worldwide [21], few recent reports have
concluded that some classes of obesity can be consid-
ered “healthy.” Findings from our study show that BMI
value was an independent prognostic factor for patients
who have gastric carcinoma with peritoneal seeding. Pa-
tients with low BMI as well as a high BMI had a worse sur-
vival rate compared with patients who had a BMI within
normal range. Previous studies have reported that patients
with higher BMI would be at higher risk for perioperative
morbidity after major abdominal cancer surgery [16, 22]. In
the study from Memorial Sloan-Kettering Cancer Center,
the results showed that higher BMI of the patients (higher
than 25) would bring longer operative time, fewer lymph
nodes, and higher complications [15]. In our study, a higher
ratio of the patients with a normal BMI underwent pallia-
tive gastrectomy, which is an important independent prog-
nostic factor, in addition to palliative chemotherapy.
However, the function of palliative gastrectomy remains
controversial, especially for the patients with peritoneal
dissemination. Some studies have suggested that palliative
gastrectomy may improve survival without increasing mor-
bidity and mortality [23, 24], while other reports have con-
tradicted this suggestion [2, 25]. Selection of patients for
palliative gastrectomy remains controversial for both
surgeons and oncologists. In our studies, we stratified the
518 patients based on receipt of palliative chemotherapy to
eliminate the influences of the palliative chemotherapy.
Among the patients who did not receive palliative chemo-
therapy, neither palliative gastrectomy nor BMI was inde-
pendent prognostic factors. Conversely, among patients who
received palliative chemotherapy, both palliative gastrectomy
and BMI were independent prognostic factors. This finding
implies that patients with a normal BMI who receive pallia-
tive chemotherapy may benefit from gastrectomy.
Table 4 Multivariate analyses of the overall survival in these
group gastric cancer patients with peritoneal dissemination
without palliative chemotherapy (Cox regression model)
Variable HR 95% CI p value
OS in gastric cancer patients
Palliative gastrectomy
(Gastrectomy vs. without gastrectomy)a
0.772 0.516–1.154 0.207
Tumor size
(<5, ≥5, and <10 vs. ≥10 cm)
1.016 0.771–1.339 0.910
Tumor location















(<18.5 and 18.5–23 vs. >23)
0.871 0.654–1.161 0.346
Abbreviations: OS overall survival, HR hazard ratio, CI confidence interval
aThe factor listed at the last was used as the control level in this Cox
regression model
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Fig. 3 The Kaplan-Meier analysis of the prognosis of this group of gastric cancer patients with peritoneal dissemination underwent palliative
chemotherapy. Palliative gastrectomy (a), tumor size (b), tumor location (c), peritoneal seeding grade (d), serum CEA level (e), and BMI group (f)
were risk factors
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As a retrospective study, there were confounding fac-
tors that may have influenced the statistical analyses and
conclusions. BMI is an important factor that reflects the
nutritional status and is correlated with postoperative
complications and long-term survival of gastric cancer.
Findings from this study suggest that gastric cancer pa-
tients with a normal BMI may benefit from palliative
gastrectomy combined with chemotherapy. Additional
experiments and clinical trials are needed to validate the
important value of BMI on the prognosis of gastric can-
cer patients with peritoneal dissemination.
Conclusions
BMI is a prognostic factor for patients who have gas-
tric cancer with peritoneal dissemination, especially in
those who received palliative chemotherapy. BMI can
be used to predict the effect of palliative chemother-
apy on these patients.
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